2023年7月20日

起見——領先的人工智能的生物醫學研究平台——最近宣布關閉6000萬B係列資金由ICONIQ增長與指數投資,參與馬拉鬆風險資本,歐洲複興開發銀行,Pentech合資企業,有遠見的俱樂部。戰略個人也參加了一輪,包括亞曆克斯Gorsky(強生公司的前董事長兼首席執行官)和奧利弗球形頂飾(Datadog開網的CEO和創始人之一)。這一最新一輪融資後公司最近增加了兩倍的收入和客戶,正在服刑12前20名的製藥公司。這些投資帶來的總資金提高到9300萬美元,將用於擴展授予的產品鉛和擴大的商業關係,使突破治療創新比以往任何時候都更快。開發一種新的藥物是一個挑戰性的過程,通常時間跨度超過十年,涉及廣泛的研究、開發和嚴格的臨床試驗。和有一個真正的緊迫感加快這個過程對於我們這個時代最複雜的和尚未解決的疾病,如帕金森症,肺癌、多發性硬化症。授予的是人工智能的解決方案是明確旨在理清這種複雜性,讓科學家們深入了解潛在疾病生物學。使用混合的方法,結合最新的高科技知識圖生成人工智能的發展,授予的使研究人員進行深入、客觀的科學探索與再現性和機構,科學探究的過程要求。和被大規模采用的技術團隊在不同工作流從目標識別生物標誌物的研究發現,與客戶包括基列、諾和諾德公司,Regeneron,美國食品和藥物管理局,國家環境健康科學研究所。這個結果是10倍的生產力增益,新奇的發現和臨床項目的成功率更高。 KEY QUOTES: “Recent advances in AI open completely new possibilities, and there is a great need for transparent AI systems that science leaders can trust. Knowledge is the lifeblood of research organizations, and we are committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.” — Yiannis Kiachopoulos, Co-founder and CEO of Causaly “We are excited to accelerate our platform investments and partner with our customers in ingesting proprietary data to truly transform the way that research is done today.” — Artur Saudabayev, Co-founder and CTO of Causaly “The sciences are at a turning point driven by the adoption of AI, and we believe Causaly is a leader in delivering this power to scientists in a highly trusted and verifiable manner. Causaly stands out to us as a uniquely powerful and user-oriented platform applying AI to drive significant productivity gains and commercial impact for many major pharmaceutical companies today. We are thrilled to support the entire Causaly team in their mission to revolutionize the way scientists find, visualize, and collaborate on scientific evidence across pharma, life sciences, and beyond.” — Caroline Xie, general partner at ICONIQ Growth and newest member of the Causaly board of directors “Causaly gives scientists the power to solve the world’s biggest challenges like never before. It is one of the clearest real-life applications of AI today. Already rolled out by some of the world’s largest pharmaceutical companies, Causaly is actively accelerating biomedical research now. We’ve been truly impressed with the level of adoption by leading research organizations, who continue to rapidly expand spend on Causaly, underlying the impact the technology is already having on R&D.” — Carlos Gonzalez-Cadenas, Partner at Index Ventures Trending on Pulse 2.0